Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 18/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16465756 | 0.89 | SIRT6 (0.58) | SIRT6BACE1BACE2APPCTSD | |
| SCHEMBL16428105 | 0.83 | SIRT6 (0.41) | SIRT6BACE1BACE2APP | |
| SCHEMBL8515335 | 0.80 | SIRT6 (0.42) | SIRT6BACE1BACE2CTSD | |
| Hydrochloric Acid SCHEMBL17497157 | 0.79 | SIRT6 (0.41) | SIRT6BACE1BACE2CTSD | |
| SCHEMBL20290961 | 0.78 | BACE1 (0.46) | BACE1BACE2CTSD | |
| SCHEMBL991588 | 0.78 | MAPT (0.56) | SIRT6 | |
| SCHEMBL839973 | 0.76 | MAPT (0.64) | — | |
| SCHEMBL9948273 | 0.76 | P4HTM (0.55) | BACE1APP | |
| SCHEMBL10328670 | 0.75 | SIRT6 (0.47) | SIRT6BACE1 | |
| SCHEMBL7935479 | 0.74 | BACE1 (0.34) | BACE1BACE2APPCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083644-B1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | HOFFMANN LA ROCHE (CH) | 2019-03-13 | — | — | EP | claimed |
| EP-2864324-B1 | DIFLUORO-HEXAHYDRO-CYCLOPENTAOXAZINYLS AND DIFLUORO-HEXAHYDRO-BENZOOXAZINYLS AS BACE1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2018-03-28 | — | — | EP | claimed |
| US-9605006-B2 | 5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines | HOFFMANN-LA ROCHE INC. (US) | 2017-03-28 | — | — | US | claimed |
| EP-2673278-B1 | N-[3-(5-AMINO-3,3A,7,7A-TETRAHYDRO-1H-2,4-DIOXA-6-AZA-INDEN-7-YL)-PHENYL]-AMIDES AS BACE1 AND/OR BACE2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2016-12-14 | — | — | EP | claimed |
| US-20160318952-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | HOFFMANN-LA ROCHE INC. (US) | 2016-11-03 | — | — | US | claimed |
| EP-3083644-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | F. Hoffmann-La Roche AG (CH) | 2016-10-26 | — | — | EP | claimed |
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | HOFFMANN-LA ROCHE INC. | 2015-11-12 | — | — | US | claimed |
| US-9181232-B2 | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-11-10 | — | — | US | claimed |
| US-9115098-B2 | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2015-08-25 | — | — | US | claimed |
| US-9073909-B2 | [1,3]oxazines | HOFFMANN-LA ROCHE INC. (US) | 2015-07-07 | — | — | US | claimed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | claimed |
| US-8404680-B2 | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | claimed |
| WO-2012168175-A1 | [1,3]OXAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | claimed |
| WO-2012139993-A1 | 1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-18 | — | — | WO | claimed |
| US-20120258962-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2012-10-11 | — | — | US | claimed |
| WO-2012107371-A1 | N-[3-(5-AMINO-3,3A,7,7A-TETRAHYDRO-1H-2,4-DIOXA-6-AZA-INDEN-7-YL)-PHENYL]-AMIDES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | claimed |
| US-20120202803-A1 | N-[3-(5-AMINO-3,3A,7,7A-TETRAHYDRO-1H-2,4-DIOXA-6-AZA-INDEN-7-YL)-PHENYL]-AMIDES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | claimed |
| EP-2483255-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-08-08 | — | — | EP | claimed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318952-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | BACE1, BACE2, PSEN1 | SIRT6 2450/4885BACE1 1/4885BACE2 2/4885 |
| US-20120202803-A1 | N-[3-(5-AMINO-3,3A,7,7A-TETRAHYDRO-1H-2,4-DIOXA-6-AZA-INDEN-7-YL)-PHENYL]-AMIDES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, IAPP | SIRT6 1384/4885BACE1 2/4885BACE2 1/4885 |
| US-20120258962-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | SIRT6 1566/4885BACE1 2/4885BACE2 1/4885 |
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | BACE2, BACE1, PSEN1 | SIRT6 1566/4885BACE1 2/4885BACE2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.